Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
6
×
biotech
fda
6
×
life sciences
national
national blog main
national top stories
new york top stories
novartis
6
×
san francisco top stories
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
clinical trials
gene therapy
ipo
europe top stories
spinal muscular atrophy
vc
venture capital
zolgensma
abbvie
allergan
What
bio
roundup
ipo
fda
new
biogen
covid
medicines
years
acquisitions
activity
allogene
america
announced
approvals
approved
atrophy
august
biotech
busy
cancer
ceo
clamped
collabs
continues
convoluted
crispr
daily
daniel
days
deal
decisions
delays
democrats
developing
devices
diversity
dreams
drug
drugs
Language
unset
Current search:
novartis
×
fda
×
biogen
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More